About this episode
The episode discusses the challenges of talking about GLP-1 medications and their impact on weight loss and health conversations.
An estimated one in eight Americans has now tried a GLP-1 medication like Ozempic or WeGovy: to lose weight, manage diabetes or experiment with anecdotal, off-label benefits. Yet GLP-1s can be hard to talk about — whether you want to ask someone if they take one, respond if you do, or discuss weight without dredging up unhealthy diet discourse. We’ll hear how you’re navigating these conversations in the age of GLP-1s. Tell us: How are GLP-1s showing up in your world? Guests: Diana Thiara, medical director, UCSF Weight Loss Management Program Whitney Casares, pediatrician; author, “Raising Body-Confident Kids” and “My One-Of A-Kind Body: The Ultimate Guide to Caring for Me” Angela Corral, senior editor, KQED’s The California Report; she has been been taking a GLP-1 for almost 2 years Learn more about your ad choices. Visit megaphone.fm/adchoices
People in this episode
Guests: Diana Thiara, Whitney Casares, Angela Corral
Topics covered
- GLP-1 medications
- weight loss
- diabetes management
- health conversations
- body confidence
Keywords
- GLP-1
- Ozempic
- WeGovy
- weight loss
- diabetes
- health discussions
- body confidence
Mentioned in this episode
Organizations: UCSF Weight Loss Management Program
Products: Ozempic, WeGovy
More episodes of KQED's Forum
- Deb Haaland on the Future of Native Leadership · June 12, 2026 · 52 min
- Olé, Olé, Olé! Expat Communities Celebrate World Cup Teams Playing in the Bay Area · June 12, 2026 · 52 min
- What Our Faces Reveal About Us · June 11, 2026 · 52 min
- What AI's Huge IPOs Will Mean for Housing Affordability in the Bay Area · June 11, 2026 · 55 min
- Ben Rhodes on the Speeches That Shaped America · June 10, 2026 · 55 min
- Trump Administration Shovels $75 million into Controversial Oakland Coal Terminal · June 10, 2026 · 55 min
Explore listener stats, chart rankings, contacts and more on the KQED's Forum podcast page.